Novartis Q1 profit down on US generic erosion
28/04/2026 06:10
April 28 (Reuters) - Swiss drugmaker Novartis NOVN.S reported first-quarter core operating profit below market expectations on Tuesday, as generic competition for its top-selling heart drug Entresto weighed on sales. Quarterly group operating income, adjusted for special items, came in at $4.9 billion, below average analyst expectations of about $5.1 billion cited by Visible Alpha. (Reporting by Marleen Kaesebier and Bhanvi Satija Editing by Ludwig Burger) ((marleen.kaesebier@thomsonreuters.com;))
Recent news on Novartis AG
See all newsBrief: Novartis Remind Data At Eaaci Show Rhapsido Potential As First Targeted Therapy For Chronic Inducible Urticaria (Cindu)
Swiss stocks - Factors to watch on June 12
Swiss pharma hub Basel frets over population cap threat
Novartis says rare muscle disease drug shows promise in early trial
Live Markets: Europe at half-time: countdown to the ECB's 'insurance hike'